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Rt Hon Theresa May MP 
2 Marsham Street 
London  
SW1P 4DF 
7th July 2010 
 
Dear Home Secretary,  
 
The ACMD indicated in its advice of 31st March 2010 on the cathinones that it 
would provide you with further advice on the naphthyl analogues of 
pyrovalerone (including naphyrone) and other such analogues. I have 
pleasure in attaching the Advisory Council on the Misuse of Drugs report on 
the ‘Consideration of the naphthylpyrovalerone analogues and related 
compounds’.  
 
The ACMD recognise the significant public health issue that ‘legal highs’ 
present. Our report references recent work on test purchases of a number of 
‘legal highs’ that demonstrate their many and varied compositions. In this 
report the evidence highlights the dangers of purchasing compounds which 
are likely to contain harmful compounds and very often will not be the same 
as the material advertised and may be more harmful and illegal. Users of 
‘legal highs’ should be acutely aware that just because it is being advertised 
as legal does not make a substance safe, nor may it be legal.  
 
Along with mephedrone and related compounds, the public health response 
should focus on the discrepancy between the compounds that are purported 
to be contained in the ‘legal high’ for sale and what the customer actually 
gets. Differences in potency between the apparently identical products could 
give rise to risk of overdose or unexpected health effects. 
 
As with mephedrone, the ACMD believes that resources should initially be 
focussed on supply side activities with a concurrent emphasis on educating 
users. Therefore the ACMD recommends that to curtail the manufacture and 
supply of naphyrone, and related compounds, an import ban is invoked with 
immediate effect.    
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The ACMD believe that naphyrone is likely to exhibit a similar spectrum of 
harmful effects as the other previously controlled cathinones. The data that 
are available for naphyrone suggest that its high potency, in comparison with 
the other cathinones, is likely to be associated with a higher risk of accidental 
overdose.  
 
The ACMD recommends that naphyrone be brought under control of the 
Misuse of Drugs Act 1971 in Class B and Schedule I of the Misuse of Drugs 
Regulations (2003 as amended) by way of a generic definition. Based on the 
attached evidence, the ACMD consider that the harms associated with 
naphyrone closely equate with compounds such as mephedrone and other 
compounds in Class B.  
 
In my letter of 31 March 2010 to your predecessor I indicated that the rapidity 
with which ‘legal highs’ have expanded has been exceptional. The ACMD 
have concerns around this trend and therefore intend to prioritise providing 
you with advice on ‘legal highs’, including advice that is wider in scope for 
protecting the public from the harms of these substances.  
 
Yours sincerely,  
 
Professor Les Iversen
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 Background 
 
1.1. In March 2009 the then Home Secretary requested advice from the 
ACMD on so called ‘legal highs’. The ACMD have looked at a number of 
substances to date and provided advice on GBL, the piperazines 
(including BZP), the synthetic cannabinoids (including ‘Spice) and 
mephedrone and related compounds.   
 
1.1. In a letter to the Home Secretary that accompanied its advice on the 
cathinones (31 March 2010) the ACMD advised that it would provide 
further advice on the naphthyl pyrovalerone analogues of cathinone.  
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 2. Introduction  
 
2.1. Naphyrone; (NRG-1; Energy1; or O-2482), naphthylpyrovalerone, is a 
naphthyl analogue of Pyrovalerone (hereafter referred to as naphyrone) 
that acts as a triple monoamine reuptake inhibitor, producing 
psychostimulant effects1.  
 
2.2. Naphyrone has close structural resemblance to the cathinones such as 
mephedrone and methylenedioxy-pyrovalerone (MDPV). Naphyrone, 
however, remains outside the generic definition in which a number of 
cathinones, including mephedrone and MDPV were controlled under the 
Misuse of Drugs Act 1971 on 16th April 2010. Since then, websites that 
had previously offered sales of mephedrone have switched to products 
purported to be naphyrone and other alternatives. Naphyrone is variously 
described as: 
 
“The replacement for mephedrone” and “A brand new designer research 
chemical ....far stronger than cocaine, amphetamine, MDMA ....” 
  
2.3. In this report it is important to distinguish between naphyrone (the 
subject of the ACMD’s advice) and NRG-1; a branded product which may 
contain naphyrone or any number of other cathinones, legal stimulants 
(caffeine) or other active and inactive constituents. The branded product 
NRG-1 cannot be presumed to be naphyrone.  
                                                 
1 Internationally pyrovalerone is controlled under Schedule IV of the 1971 UN Conventions. 
 5
 3. Chemical Structure 
 
3.1. Naphyrone, is a naphthyl analogue of the cathinones and has close 
resemblance to pyrovalerone, see Figure 1. Pyrovalerone was used 
clinically to treat lethargy and fatigue due to its stimulant effects (Gardos 
and Cole 1971), but its clinical use was largely discontinued due to its 
association with risks of abuse and addiction (Deniker et al, 1975). 
Pyrovalerone was controlled as a Class C drug under the Misuse of Drugs 
Act 1971 prior to the inclusion of other cathinones in April 2010.  
 
3.2. Meltzer and co-workers (2006) have described the synthesis of 
naphyrone and a whole range of structurally related pyrovalerone 
analogues in an attempt to study their ability to release the monoamine 
neurotransmitters dopamine, serotonin and norepinephrine in the brain.  
 
3.3. Naphyrone is more difficult to make than mephedrone and the other 
legal highs controlled by the cathinone generic classification introduced in 
April 2010. Its synthesis involves simple reactions, however, the starting 
materials are not as readily available as the reagents needed for the 
synthesis of the simpler cathinones such as mephedrone. 
 
3.4. The majority of samples purported to contain naphyrone which have 
been analyzed to date contain other materials such as mephedrone, 
butylone and other related compounds. However, it is highly possible that 
the chemists who supply the legal high websites are ‘dumping’ their old 
stocks of cathinones (which are now controlled by the generic 
classification) under the trade name naphyrone (NRG-1). This is fraught 
with potential problems (see below), particularly if genuine naphyrone 
becomes more widely available as the dose required is ten-fold less than 
for mephedrone and this could lead to a significant risk of overdose. 
 
Figure 1. Naphyrone, pyrovalerone, MDPV and mephedrone 
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 4. Pharmacology 
 
4.1. There is limited published information on the pharmacology of 
naphyrone. However, there is considerable pharmacological risk potential 
in this compound due to its potency, relative to other drugs e.g. 
mephedrone. Naphyrone has been shown in vitro to affect the reuptake 
of the neurotransmitters dopamine, serotonin and norepinephrine by 
inhibition of the human monoamine transporters (termed: NET = 
norepinephrine transporter; SERT = serotonin transporter; and DAT = 
dopamine transporter).  
 
4.2. These transporters are responsible for inactivating the 
neurotransmitters after their release in the brain, thus making more 
neurotransmitter available. The drugs may also be taken up by the 
transporters into nerve endings where they cause a release of the stored 
neurotransmitter. There are three distinct transporters present in nerves 
using the three monoamine neurotransmitters. 
 
4.3. Naphyrone has considerable abuse potential since it is a triple uptake 
inhibitor that demonstrates high potency values for inhibition of each of 
the neurotransmitters2. Drugs such as d-amphetamine which interact 
selectively with the dopamine transporter (DAT) have psychostimulant 
properties in human users; those such as MDMA (ecstasy) that interact 
selectively with the serotonin transporter (SERT) have “empathogenic” 
profiles; while triple uptake inhibitors such as cocaine combine these 
properties.   
 
4.4. Table 1 shows that the potencies of this inhibition are in the low nano-
molar (nM) range making naphyrone a potent ‘broad-spectrum’ 
neurotransmitter releaser which distinguishes this compound from other 
cathinones. These results predict that naphyrone may have a “cocaine-
like” profile, but with approximately ten times higher potency than 
cocaine. Early reports from human users of naphyrone appear to confirm 
that the pharmacological dose is indeed very low. 
 
 
 
 
 
 
                                                 
2 DA = dopamine, a neurotransmitter involved in the regulation of movement function, energy 
and drive, appetitive, drug-liking and drug dependence. 5-HT = serotonin, a neurotransmitter 
involved in many brain functions including regulation of mood and anxiety, eating, sleeping, 
sexual function and cognition. NE = norepinephrine (noradrenalin), a neurotransmitter 
involved in the brain and in the peripheral sympathetic nervous system. Drug-induced release 
of NE in the periphery leads to stimulation of heart and raised blood pressure. 
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 Table 1. Potencies of naphyrone as monoamine uptake inhibitor 
compared with other drugs of use3 
 
 DA1 uptake-nM 5-HT uptake-nM NE uptake -nM 
Pyrovalerone     52 >10,000   56 
Naphyrone     40     46   12 
MDMA (Ecstasy) 1572   238   46 
d-Amphetamine     34 3830   39 
Cocaine   461   494 378 
 
 
                                                 
3 Data from Meltzer et al (2006) and Rothman & Baumann (2003). Values represent the drug 
concentrations (in nanomolar ) required for 50% inhibition of monoamine uptake in test tube 
model in vitro. Lower numbers indicate increased drug potency. 
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 5. Prevalence 
 
5.1. The current prevalence of naphyrone use is unknown. However, many 
of the websites that were previously selling mephedrone now purport to be 
selling naphyrone through the brand name NRG-1.   
 
5.2. Some naphyrone suppliers are marketing the drug for as little as 25p a 
dose (£12.50 / gram) (or 1kg for £2,500). Some internet based retailers 
are selling naphyrone (NRG-1) as a premium based plant food or pond 
cleaner.   
 
5.3. The government acted on ACMD advice to control mephedrone and 
other substituted cathinones, under the Misuse of Drugs Act 1971, on the 
29th March 2010 -  these became controlled drugs on 16th April 2010. It is 
a concern that Google trends data on NRG-1 searches indicates a spike in 
searches in the latter half of April 2010.  
 
Test Purchasing  
5.4. A publication by Davies et al (2010), references test purchases made 
from the ‘legal highs’ market before the 2010 legislation concerning the 
cathinones. The paper does not reference NRG-1 as a branded product. 
 
5.5. However, a publication by Brandt et al (2010) from Liverpool John 
Moores University showed analyses of test purchases in April-May 2010. 
The ‘legal highs’ purchased were marketed as NRG-1, NRG-2 and MDAI 
(purchasers probably assuming these to be and/or product descriptions 
being; naphyrone, dimethocaine and 5,6-methylenedioxy-2-aminoindane 
respectively). Of seventeen products purchased from 12 UK-based 
websites following the ban on mephedrone and related compounds, 
composition varied dramatically and represented a range of controlled 
compounds and did not, in the main, reflect the product description.  
 
5.6. Test purchasing, of a relatively small number of samples, conducted by 
Tic Tac Communications has shown that naphyrone is often mislabeled, 
and the substance sold is often a combination of MDPV and/or butylone 
(results to be published). However, genuine samples of naphyrone have 
also been detected.  
 
5.7. The mislabeling of products may reflect a temporary shortage of 
supply, or a desire to offload cathinones and other compounds that could 
previously have been sold legally.   
 
5.8. The Association of Chief Police Officers in Scotland (ACPOS) 
announced that NRG-1 is becoming extensively available throughout 
Scotland, with the drug advertised as a legal product through UK 
websites and ‘expert’ stores. However, tested samples have been shown 
to contain methylenedioxy-pyrovalerone (MDPV) – a substance brought 
into Class B of the Misuse of Drugs Act 1971 in April 2010. 
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 5.9. Limited samples of test purchasing would suggest that the prevalence 
of the compound naphyrone is currently relatively low and makes up a 
relatively small percentage of the total compounds found in marketed 
‘legal highs’.  
 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)  
5.10. The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) has announced that they have received a ‘Reporting Form’ 
from the Swedish National Focal Point, notifying two seizures of powder 
of 10g and 288g of naphyrone respectively.  
 
5.11. The EMCDDA has opened a new profile for naphyrone4 and has 
requested analytical details to facilitate its identification. 
                                                 
4 The EMCDDA gives drug profiles containing descriptions of drugs in the form of public 
access ‘drug profiles’ located at: http://www.emcdda.europa.eu/publications/drug-profiles. The 
profiles are presented in a standardised way, each profile briefly gives the chemistry, 
pharmacology, synthesis and precursors of each substance, as well as analysis, physical 
form (e.g. powder, tablet) and mode of use (e.g. ingested, snorted, injected). 
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 6. Physical harms  
 
Routes of administration 
6.1. Naphyrone is usually sold as a white crystalline powder. 
 
6.2. As with other so-called ‘legal highs’, users of NRG-1 (believing it to 
contain naphyrone) may insufflate or swallow the substance, either by 
dabbing a moistened finger into the product or wrapping in a cigarette 
paper and ‘bombing’. Given the very small quantities required for an 
active dose of naphyrone, these methods of administration provide an 
unreliable measure of dosage. 
 
Adverse Effects 
6.3. Currently very little safety or toxicity data are available for naphyrone, 
but its high potency by comparison with previous cathinones or MDMA 
(ecstasy) suggests that its use is likely to be associated with a higher risk 
of accidental overdose. It is apparent that some suppliers are aware of 
this and recommend a dose as small as 0.02g, by comparison with the 5-
10 times higher doses associated with MDMA or mephedrone.  
 
6.4. Consistent with the known or reported harms of the cathinones and 
traditional amphetamines the predicted harmful effects of naphyrone 
include adverse effects on the heart and blood vessels, hyperthermia, 
dependence liability, and psychiatric effects including psychosis and 
anxiety. In extreme cases amphetamine-like drugs can cause death due 
to cardiovascular collapse or heat shock (ACMD Report on Cathinones, 
March 2010). 
 
6.5. Another long term concern is that substances containing naphthyl 
substituents are generally avoided in medicinal chemistry, owing to their 
potential risk as carcinogens, possibly after metabolism of the naphthyl 
ring to a highly reactive naphthalene epoxide (Clayson et al, 1958). The 
clinical development of the beta-blocker pronethanol, for example, which 
bears some close structural resemblance to naphyrone, was abandoned 
because of its carcinogenicity in animal tests (Howe,1965; Stapleton, 
2007). 
 
 
Prothenalol 
 
 
Accident and Emergency Presentations  
6.6. Guy's and St Thomas' Hospital have seen individuals presenting with 
acute recreational drug toxicity where use of NRG-1 was reported. 
However, toxicological analysis of biological samples from these 
individuals did not detect naphyrone, but instead detected a combination 
of other cathinones. Therefore, there have been no confirmed cases of 
 11
 acute toxicity associated with the use of naphyrone. It is therefore 
apparent that NRG-1 may not often contain controlled substances, such 
as other cathinones, rather than naphyrone. 
  
6.7. Two further cases of potential NRG-1 use have been reported by the 
North Wales Police, following which two individuals were taken to 
Wrexham Mealier Hospital. It remains unclear whether the substance the 
individuals took was naphyrone.    
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 7. Societal harms 
 
Anti-social behaviour / acquisitive crime  
7.1. The ACMD is not aware of any relationship between naphyrone and 
anti-social behaviour or acquisitive crime.  
 
Organised crime 
7.2. It would appear that, at present, the retail trade in NRG-1 (purported to 
be naphyrone) and other emergent so-called legal highs operates mainly 
through importation and distribution via internet websites; many of which 
were previously marketing mephedrone and other substituted cathinones 
controlled in the UK in April 2010.  
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 8. Conclusions 
 
Public Health 
8.1. The ACMD consider that the public health response to naphyrone, 
related compounds and other legal highs is a pressing issue.  
 
8.2. The control of mephedrone and other cathinones under the Misuse of 
Drugs Act 1971 appears to have precipitated a shift in the products now 
offered for sale on the internet. This includes products marketed as 
naphyrone (NRG-1), but also a range of other compounds e.g. NRG-2 
and MDAI (purported to be 5,6-methylenedioxy-2-aminoindane). 
Subsequent test purchase and analysis of these ‘new’ so-called ‘legal 
highs’ shows that the composition of these products varies and is rarely 
the purported product for sale (Brandt et al, 2010). From the limited 
samples analysed, from test purchasing, it appears that the market has 
changed the branding of products rather than changed the products 
themselves.  
 
8.3. The ACMD have identified two concerns about this development. 
Firstly, the users of ‘legal highs’ may be at least partially motivated by a 
desire to buy a legal psychoactive substance rather than an illegal one. 
However, test purchasing would suggest that in fact there is a 
considerable risk that they are inadvertently purchasing an illegal 
substance. Secondly, and of considerable concern as mentioned above, 
is the potential for overdose: users who purchase a named product, when 
purchasing that product for a subsequent time, may receive a product of 
different composition to their first purchase. Differences in potency 
between the apparently identical branded products could give rise to risk 
of overdose or unexpected pharmacological effects. This is particularly 
significant in the case of NRG-1: whilst analyses suggest that NRG-1 is 
currently likely to contain varying mixtures of controlled substituted 
cathinones, if this changes to naphyrone (of much higher potency than 
substituted cathinones), the risk of overdose is much higher.  
 
8.4. The potency of naphyrone is such that users only require a dose of 
approximately 25mg to have an effect. Since this dose is a very small 
amount it is unlikely that users will be able to, with any accuracy, 
measure out this amount.   
 
8.5. Given the significant legal and health risks to users outlined in 8.3 and 
8.4, a concerted public health and education campaign is required which 
highlights the inconsistencies in the content of these products, the 
variable potency, risk of overdose and the possibility that users are 
purchasing drugs which are already controlled under the Misuse of Drugs 
Act 1971.  
 
Importation, control (under the Misuse of Drugs Act 1971) and regulation 
8.6. The ACMD considered four options that are presented in Annex 1. 
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 8.7. The ACMD consider that the harms associated with naphyrone and 
related compounds are commensurate with those of mephedrone and 
therefore those substances in Class B; therefore the ACMD recommend 
that naphyrone and its close structural analogues be controlled as Class B 
substances under the Misuse of Drugs Act 1971.  
 
8.8. The ACMD recommend that naphyrone and related compounds should 
be controlled by a generic definition under the Misuse of Drugs Act 1971 – 
see Annex 1 (option 4), and in schedule 1 of the Misuse of Drugs 
Regulations 2001 (as amended). 
 
8.9. Furthermore, the ACMD recommend that, with immediate effect, the 
government introduce an import ban by amending the Open General 
Import Licence (OGIL) to exclude naphyrone from its scope; thereby 
creating a ban under the Import of Goods Control Order 1954.  
 
Reference compounds and analysis  
8.10. There is an urgent need for a national chemistry resource capable of 
providing such reference samples as novel psychoactive substances 
emerge. The ACMD note that the lack of availability of certified standards 
of naphyrone could create a problem with the forensic analysis of 
potential naphyrone samples; this may be met by a recommendation to 
Research Councils to initiate research calls in this area. 
 
8.11. The present availability and manufacture of reference compounds and 
analytical capability may hamper forensic testing and any subsequent 
enforcement response to legislative changes.  
 
8.12. The ACMD further note the need for research on emergent trends in 
drug use, their consequences and the implications for drug policy, which 
should be seen as a priority for the social research community and social 
science research bodies. 
 
Uses 
8.13. The ACMD are unaware of any medical or industrial uses of the 
compounds covered by the generic scope advised.   
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 9. Recommendations  
 
The ACMD make the following recommendations:  
 
9.1. A public health and education campaign which warns of the harms 
likely to be associated with naphyrone. The campaign should also 
highlight the inconsistencies in the content of these products, the variable 
potency, risk of overdose and the possibility that users are purchasing 
drugs which are already controlled under the Misuse of Drugs Act 1971.  
 
9.2. Naphyrone and related compounds should be controlled as Class B 
substances by a generic definition under the Misuse of Drugs Act 1971, 
and in schedule 1 of the Misuse of Drugs Regulations 2001 (as amended). 
 
9.3. The government introduce an import ban on naphyrone with immediate 
effect.  
 
9.4. The resource capability for providing reference samples, as novel 
psychoactive substances emerge, should be strengthened.  
 
9.5. Research on emergent trends in drug use (‘legal highs’), their 
consequences and the implications for drug policy, should be seen as a 
priority for the social research community and social science research 
bodies. 
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Annex 1. Options considered by the ACMD 
 
Option 1 
Encourage greater reporting and evidence gathering and provide further 
advice to ministers as information becomes available. 
 
Option 2 
Classify as a stand alone substance; so that naphthylpyrovalerone (NRG-1) is 
controlled under the Misuse of Drugs Act 1971. This would bring 
naphthylpyrovalerone into line with other cathinones therefore closing the 
loop-hole that currently exists.  
 
Option 3 
Invoke the open general licence to ban the import of naphthylpyrovalerone – 
this would be in conjunction with options 1, 2 or 4.  
 
Option 4 
Extend the generic definition of the cathinones to include 
naphthylpyrovalerone (NRG-1) therefore allowing naphyrone to be controlled 
under the Misuse of Drugs Act 1971. The recommended definition is: 
 
“Any compound structurally derived from 2-aminopropan-1-one by substitution 
at the 1-position with any monocyclic, or fused-polycyclic ring system (not 
being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the 
compound is further modified in any of the following ways, that is to say, 
(i) by substitution in the ring system to any extent with alkyl, alkoxy, 
haloalkyl or halide substituents, whether or not further substituted in 
the ring system by one or more other univalent substituents; 
(ii) by substitution at the 3-position with an alkyl substituent; 
(iii)   by substitution at the 2-amino nitrogen atom with alkyl or dialkyl 
groups, or by inclusion of the 2-amino nitrogen atom in a cyclic 
structure.” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Annex 2. Drugs controlled under the proposed generic definition (the list is not exhaustive) 
Name and Structure DAT (Ki) SERT (Ki) NET (Ki) Ref Within Scope 
Naphyrone, O-2482, NRG-1, 
[Naphthylene analogue of pyrovalerone] 
O
N
 
20.1 199 37.8 Meltzer et al., 
2006  
Yes 
[naphth-1-yl isomer of naphyrone] 
O
N
 
? ? ? ? Yes 
N-Methyl analogue of naphyrone 
 
? ? ? ? Yes 
Methylenedioxy analogue of naphyrone 
O
N
O
O  
? ? ? ? Yes 
[fused 
polycyclic ring 
system] 
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 Name and Structure DAT (Ki) SERT (Ki) NET (Ki) Ref Within Scope 
Methylenedioxy analogue of naphyrone 
 
? ? ? ? Yes 
[fused 
polycyclic ring 
system] 
[Tetralin analogue of naphyrone] 
 
? ? ? ? Yes 
Quinoline analogue of naphyrone 
 
? ? ? ? Yes 
[Compound 3] 
O H
N
S  
>10uM >10uM >10uM Lancelot et al., 
1992 
Yes 
Pyridine analogue of pyrovalerone 
N
O
N
 
? ? ? ? Yes 
 20 
 Name and Structure DAT (Ki) SERT (Ki) NET (Ki) Ref Within Scope 
Cyclohexane analogue of mephedrone 
 
? ? ? ? Yes 
[Compound 17] 
 
70 ? ? Carroll et al., 
2009 
Yes 
 
? ? ? ? Yes 
Morpholino analogue of mephedrone 
 
? ? ? ? Yes 
Alkylene derivative of mephedrone 
 
? ? ? ? Yes 
 21 
 22 
Name and Structure DAT (Ki) SERT (Ki) NET (Ki) Ref Within Scope 
 
Alkyleneoxy derivative of mephedrone 
 
? ? ? ? Yes 
Bromo-DragonFLY analogue 
O
 
? ? ? ? Yes 
NH2
O
O
Br
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